Status:
COMPLETED
Induction Cisplatin and Capecitabine Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma
Lead Sponsor:
The University of Hong Kong-Shenzhen Hospital
Conditions:
Nasopharyngeal Carcinoma
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
To prospectively evaluate the short-term efficacy and toxicity of induction chemotherapy with cisplatin and capecitabine followed by concurrent chemoradiotherapy (CCRT) in the treatment of locally adv...
Detailed Description
All patients received 3 cycles of induction chemotherapy:cisplatin 80mg/m2, day 1; oral capecitabine 1000mg/m2 twice daily from day1-14, repeated every 3 weeks followed by concomitant cisplatin (100mg...
Eligibility Criteria
Inclusion
- Pathological confirmed nasopharyngeal carcinoma.
- Staged as III to IVB.
- 18-75 years old.
- Performance status ≤2.
- No previous chemotherapy or radiotherapy.
- No concurrent malignancies or a history of other malignancies.
- Adequate bone marrow function (absolute neutrophil count ≥1.5×109/L, platelets ≥100×109/L).
- Adequate liver and renal function (serum bilirubin and serum transaminase levels less than twice the upper limit of normal, creatinine clearance ≥ 60ml/min).
- Without serious co-morbidity.
Exclusion
- Stage I-II or IVC.
- Allergic to cisplatin or capecitabine
- Age \<18 or \>75
- Performance Status \>2.
- Without adequate bone marrow or liver function or renal function.
- Severe co-morbidity and can not tolerate chemotherapy.
- Other conditions not suitable for the study on the discretion of charging doctor.
Key Trial Info
Start Date :
January 22 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2017
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT03427359
Start Date
January 22 2015
End Date
December 31 2017
Last Update
February 9 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.